Lipella Pharmaceuticals Inc.(LIPO)Earnings, Financials & Key Ratios
LIPO•NASDAQ
$0.02
$23584 mkt cap·Price updated May 6, 2026
AboutLipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.Show more
- Revenue$536K+19.3%
- EBITDA-$5M-7.0%
- Net Income-$5M-8.6%
- EPS (Diluted)-4.79+22.2%
- Gross Margin-573.65%+0.4%
- EBITDA Margin-946.69%+10.3%
- Operating Margin-947.23%+10.3%
- Net Margin-935.25%+9.0%
- ROE-198.12%-67.7%
- Debt/Equity0.02-42.9%
LIPO Key Insights
Lipella Pharmaceuticals Inc. (LIPO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.0x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 1 (bottom 1%)
- ✗Sales declining 5.0% over 5 years
- ✗Shares diluted 39.7% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
LIPO Price & Volume
Lipella Pharmaceuticals Inc. (LIPO) stock price & volume — 10-year historical chart
Loading chart...
LIPO Growth Metrics
Lipella Pharmaceuticals Inc. (LIPO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-5.04%
3 Years27.41%
TTM-64.08%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-29410.04%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM41.31%
Return on Capital
10 Years-114.59%
5 Years-114.59%
3 Years-132.79%
Last Year-198.8%
LIPO Peer Comparison
Lipella Pharmaceuticals Inc. (LIPO) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SIGA | 336.57M | 4.70 | 14.24 | -31.8% | 24.64% | 0% | 0 | |
 NUVL | 6.92B | 104.26 | -26.53 | -45.12% | ||||
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 ALDX | 104.68M | 1.74 | -1.85 | -87.71% | 0.22 | |||
 RCKT | 418.11M | 3.86 | -1.92 | -80.49% | 0.09 | |||
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 PHAT | 1.01B | 12.67 | -4.18 | 216.93% | -61.95% |
Compare LIPO vs Peers
Lipella Pharmaceuticals Inc. (LIPO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LIPO Income Statement
Lipella Pharmaceuticals Inc. (LIPO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 694.75K | 961.68K | 259.35K | 184.16K | 449.62K | 536.36K | 173.67K |
| Revenue Growth % | - | 38.42% | -73.03% | -28.99% | 144.15% | 19.29% | -64.08% |
| Cost of Goods Sold | 682.89K | 975.96K | 1.46M | 2.55M | 3.04M | 3.61M | 2.85M |
| COGS % of Revenue | 98.29% | 101.48% | 561.71% | 1383.43% | 675.87% | 673.65% | - |
| Gross Profit | 11.86K▲ 0% | -14.28K▼ 220.4% | -1.2M▼ 8287.2% | -2.36M▼ 97.4% | -2.59M▼ 9.5% | -3.08M▼ 18.8% | -2.67M▲ 0% |
| Gross Margin % | 1.71% | -1.48% | -461.71% | -1283.43% | -575.87% | -573.65% | -1539.58% |
| Gross Profit Growth % | - | -220.41% | -8287.22% | -97.38% | -9.55% | -18.83% | - |
| Operating Expenses | 65.65K | 42.59K | 718.38K | 226.19K | 2.16M | 2M | 1.28B |
| OpEx % of Revenue | 9.45% | 4.43% | 277% | 122.83% | 479.68% | 373.58% | - |
| Selling, General & Admin | 65.65K | 42.59K | 718.38K | 226.19K | 2.16M | 2M | 554.98M |
| SG&A % of Revenue | 9.45% | 4.43% | 277% | 122.83% | 479.68% | 373.58% | - |
| Research & Development | 682.89K | 975.96K | 1.46M | 2.55M | 0 | 0 | 722.04M |
| R&D % of Revenue | 98.29% | 101.48% | 561.71% | 1383.43% | - | - | - |
| Other Operating Expenses | -682.89K | -975.96K | -1.46M | -2.55M | 0 | 0 | -1.22M |
| Operating Income | -53.79K▲ 0% | -56.86K▼ 5.7% | -1.92M▼ 3269.3% | -2.59M▼ 35.2% | -4.75M▼ 83.3% | -5.08M▼ 7.0% | -1.28B▲ 0% |
| Operating Margin % | -7.74% | -5.91% | -738.71% | -1406.26% | -1055.55% | -947.23% | -736130.09% |
| Operating Income Growth % | - | -5.71% | -3269.26% | -35.17% | -83.26% | -7.05% | - |
| EBITDA | 0 | -53.69K | -1.86M | -2.59M | -4.74M | -5.08M | -1.28B |
| EBITDA Margin % | - | -5.58% | -716.66% | -1405.37% | -1055.18% | -946.69% | -734883.03% |
| EBITDA Growth % | - | - | -3361.73% | -39.25% | -83.31% | -7.03% | -29198.81% |
| D&A (Non-Cash Add-back) | 53.79K | 0 | 0 | 0 | 1.69K | 2.89K | 2.17M |
| EBIT | -53.79K | -53.69K | -1.86M | -2.59M | -4.61M | -5.02M | -1.26B |
| Net Interest Income | -8.06K | -4.79K | -6.73K | -7.93K | 126.99K | 64.28K | 60.01K |
| Interest Income | 334 | 3.17K | 104 | 1.68K | 137.84K | 64.28K | 60.01K |
| Interest Expense | 8.39K | 7.96K | 6.83K | 9.61K | 10.85K | 0 | 0 |
| Other Income/Expense | -8.06K | -4.79K | 50.35K | -7.98K | 126.99K | 64.28K | 20.25M |
| Pretax Income | -61.85K▲ 0% | -61.66K▲ 0.3% | -1.87M▼ 2925.6% | -2.6M▼ 39.3% | -4.62M▼ 77.8% | -5.02M▼ 8.6% | -1.26B▲ 0% |
| Pretax Margin % | -8.9% | -6.41% | -719.3% | -1410.59% | -1027.31% | -935.25% | -724467.47% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -61.85K▲ 0% | -61.66K▲ 0.3% | -1.87M▼ 2925.6% | -2.6M▼ 39.3% | -4.62M▼ 77.8% | -5.02M▼ 8.6% | -1.26B▲ 0% |
| Net Margin % | -8.9% | -6.41% | -719.3% | -1410.59% | -1027.31% | -935.25% | -724467.47% |
| Net Income Growth % | - | 0.31% | -2925.61% | -39.25% | -77.81% | -8.6% | -29410.04% |
| Net Income (Continuing) | -61.85K | -61.66K | -1.87M | -2.6M | -4.62M | -5.02M | -1.26B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.24▲ 0% | -0.23▲ 4.2% | -4.38▼ 1804.3% | -5.12▼ 16.9% | -6.16▼ 20.3% | -4.79▲ 22.2% | -276.57▲ 0% |
| EPS Growth % | - | 4.17% | -1804.35% | -16.89% | -20.31% | 22.24% | 41.31% |
| EPS (Basic) | -0.24 | -0.23 | -4.00 | -5.12 | -6.16 | -4.79 | - |
| Diluted Shares Outstanding | 260K | 266.4K | 426.01K | 507.58K | 750.38K | 1.05M | 4.55M |
| Basic Shares Outstanding | 260K | 266.4K | 466.48K | 507.36K | 749.83K | 1.05M | 4.55M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
LIPO Balance Sheet
Lipella Pharmaceuticals Inc. (LIPO) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 118.92K | 699.43K | 1.81M | 5.8M | 3.43M | 2.62M | 2.08B |
| Cash & Short-Term Investments | 26K | 606.74K | 1.71M | 5.12M | 3.29M | 2.18M | 1.86B |
| Cash Only | 26K | 606.74K | 1.41M | 5.12M | 3.29M | 2.18M | 1.86B |
| Short-Term Investments | 0 | 0 | 300.55K | 0 | 0 | 0 | 0 |
| Accounts Receivable | 83.89K | 69.03K | 0 | 113.66K | 32.29K | 84.71K | 0 |
| Days Sales Outstanding | 44.07 | 26.2 | - | 225.27 | 26.21 | 57.65 | 111.56 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 223.52M |
| Total Non-Current Assets | 0 | 255.59K | 204.8K | 150.82K | 147.89K | 56.62K | 270.52M |
| Property, Plant & Equipment | 0 | 255.59K | 204.8K | 150.82K | 147.89K | 56.62K | 262.82M |
| Fixed Asset Turnover | - | 3.76x | 1.27x | 1.22x | 3.04x | 9.47x | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 7.7M |
| Total Assets | 118.92K▲ 0% | 955.02K▲ 703.1% | 2.01M▲ 110.8% | 5.95M▲ 195.6% | 3.58M▼ 39.9% | 2.67M▼ 25.3% | 2.35B▲ 0% |
| Asset Turnover | 5.84x | 1.01x | 0.13x | 0.03x | 0.13x | 0.20x | 0.00x |
| Asset Growth % | - | 703.1% | 110.77% | 195.6% | -39.88% | -25.25% | 108782.08% |
| Total Current Liabilities | 165.67K | 207.77K | 340.63K | 1.18M | 385.36K | 754.42K | 642.4M |
| Accounts Payable | 49.34K | 24.54K | 46.9K | 384.36K | 138.02K | 388.19K | 462.89M |
| Days Payables Outstanding | 26.37 | 9.18 | 11.75 | 55.07 | 16.58 | 39.21 | 14.88K |
| Short-Term Debt | 50K | 82.04K | 25K | 275K | 0 | 0 | 44.27M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 40.04K | 0 | 0 | 0 | 0 | 0 | 135.24M |
| Current Ratio | 0.72x | 3.37x | 5.31x | 4.92x | 8.90x | 3.47x | 3.47x |
| Quick Ratio | 0.72x | 3.37x | 5.31x | 4.92x | 8.90x | 3.47x | 3.47x |
| Cash Conversion Cycle | - | - | - | - | - | - | -14.77K |
| Total Non-Current Liabilities | 71.59K | 283.94K | 248.71K | 96.26K | 47.37K | 0 | 219.82M |
| Long-Term Debt | 50K | 50K | 50K | 0 | 0 | 0 | 219.82M |
| Capital Lease Obligations | 0 | 207.96K | 168.36K | 96.26K | 47.37K | 0 | 231.64K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 21.59K | 25.97K | 30.35K | 0 | 0 | 0 | 1 |
| Total Liabilities | 237.26K | 491.7K | 589.34K | 1.27M | 432.73K | 754.42K | 862.22M |
| Total Debt | 100K | 388.91K | 282.96K | 429.52K | 136.59K | 47.6K | 264.08M |
| Net Debt | 74K | -217.82K | -1.13M | -4.69M | -3.16M | -2.14M | -1.59B |
| Debt / Equity | - | 0.84x | 0.20x | 0.09x | 0.04x | 0.02x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - | -0.21x |
| Net Debt / EBITDA | - | - | - | - | - | - | 1.25x |
| Interest Coverage | -6.41x | -7.14x | -280.34x | -269.42x | -437.50x | - | - |
| Total Equity | -118.34K▲ 0% | 463.32K▲ 491.5% | 1.42M▲ 207.3% | 4.68M▲ 228.4% | 3.14M▼ 32.7% | 1.92M▼ 39.0% | 1.49B▲ 0% |
| Equity Growth % | - | 491.51% | 207.25% | 228.45% | -32.75% | -38.96% | 101946.86% |
| Book Value per Share | -0.46 | 1.74 | 3.34 | 9.21 | 4.19 | 1.83 | 327.01 |
| Total Shareholders' Equity | -118.34K | 463.32K | 1.42M | 4.68M | 3.14M | 1.92M | 1.49B |
| Common Stock | 520 | 574 | 387 | 574 | 605 | 121 | 462K |
| Retained Earnings | 0 | -1.24M | -3.11M | -5.7M | -10.32M | -15.34M | -19.23B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.18M | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LIPO Cash Flow Statement
Lipella Pharmaceuticals Inc. (LIPO) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -39.12K | -28.58K | -989.27K | -1.83M | -3.15M | -3.95M | -3.95M |
| Operating CF Margin % | -5.63% | -2.97% | -381.45% | -994.35% | -700.63% | -736.59% | - |
| Operating CF Growth % | - | 26.94% | -3361.77% | -85.1% | -72.03% | -25.41% | -361003.99% |
| Net Income | -61.85K | -61.66K | -1.87M | -2.6M | -4.62M | -5.02M | -1.26B |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 1.69K | 2.89K | 2.17M |
| Stock-Based Compensation | 0 | 57.71K | 728.8K | 747.4K | 1.36M | 749.4K | 80.67K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 18.73K | 7.64K | -50.21K | 9.61K | 121.2K | 200K | 1.53B |
| Working Capital Changes | 14.34K | -32.28K | 197.61K | 9.52K | -9.11K | 113.23K | 369.87K |
| Change in Receivables | -43.78K | 14.86K | 69.03K | -113.66K | 0 | 0 | 0 |
| Change in Inventory | 0 | -14.86K | 0 | 113.66K | 0 | 0 | 0 |
| Change in Payables | 33.44K | -24.8K | 22.36K | 337.46K | -246.34K | 250.18K | 74.63M |
| Cash from Investing | 0 | 0 | -300.55K | 300.55K | -14.43K | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | -14.43K | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | 3.21% | 0% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -300.55M | 0 | 0 | 0 |
| Cash from Financing | 25K | 609.31K | 2.1M | 5.24M | 1.34M | 2.84M | 4.22B |
| Debt Issued (Net) | 25K | 57.04K | 0 | 275K | -275K | 0 | 0 |
| Equity Issued (Net) | 0 | 552.27K | 1000K | 1000K | 1000K | 1000K | 1.99M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | 0 | 0 | 4.21B |
| Net Change in Cash | -14.12K▲ 0% | 580.73K▲ 4213.7% | 807.09K▲ 39.0% | 3.71M▲ 359.4% | -1.83M▼ 149.3% | -1.11M▲ 39.3% | 1.85B▲ 0% |
| Free Cash Flow | -39.12K▲ 0% | -28.58K▲ 26.9% | -989.27K▼ 3361.8% | -1.83M▼ 85.1% | -3.16M▼ 72.8% | -3.95M▼ 24.8% | -2.36B▲ 0% |
| FCF Margin % | -5.63% | -2.97% | -381.45% | -994.35% | -703.84% | -736.59% | -1359858.31% |
| FCF Growth % | - | 26.94% | -3361.77% | -85.1% | -72.82% | -24.84% | -63934.26% |
| FCF per Share | -0.15 | -0.11 | -2.32 | -3.61 | -4.22 | -3.77 | -3.77 |
| FCF Conversion (FCF/Net Income) | 0.63x | 0.46x | 0.53x | 0.70x | 0.68x | 0.79x | 1.88x |
| Interest Paid | 0 | 0 | 0 | 0 | 11.36K | 11.91K | 7.93K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LIPO Key Ratios
Lipella Pharmaceuticals Inc. (LIPO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -35.75% | -197.73% | -85.18% | -118.13% | -198.12% | -84.58% |
| Return on Invested Capital (ROIC) | -42.4% | -533.98% | -1407.16% | - | - | 6256.97% |
| Gross Margin | -1.48% | -461.71% | -1283.43% | -575.87% | -573.65% | -1539.58% |
| Net Margin | -6.41% | -719.3% | -1410.59% | -1027.31% | -935.25% | -724467.47% |
| Debt / Equity | 0.84x | 0.20x | 0.09x | 0.04x | 0.02x | 0.02x |
| Interest Coverage | -7.14x | -280.34x | -269.42x | -437.50x | - | - |
| FCF Conversion | 0.46x | 0.53x | 0.70x | 0.68x | 0.79x | 1.88x |
| Revenue Growth | 38.42% | -73.03% | -28.99% | 144.15% | 19.29% | -64.08% |
LIPO Frequently Asked Questions
Lipella Pharmaceuticals Inc. (LIPO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Lipella Pharmaceuticals Inc. (LIPO) reported $0.2M in revenue for fiscal year 2024. This represents a 75% decrease from $0.7M in 2019.
Lipella Pharmaceuticals Inc. (LIPO) grew revenue by 19.3% over the past year. This is strong growth.
Lipella Pharmaceuticals Inc. (LIPO) reported a net loss of $1.26B for fiscal year 2024.
Dividend & Returns
Lipella Pharmaceuticals Inc. (LIPO) has a return on equity (ROE) of -198.1%. Negative ROE indicates the company is unprofitable.
Lipella Pharmaceuticals Inc. (LIPO) had negative free cash flow of $2.36B in fiscal year 2024, likely due to heavy capital investments.
Explore More LIPO
Lipella Pharmaceuticals Inc. (LIPO) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates